«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

20卷

期数:

2014年05期

页码:

379-382

栏目:

临床医学

出版日期:

2014-09-20

文章信息/Info

Title:

 Influence of complications on early survival of patients with localized or locally advanced prostate cancer

文章编号:

1006-8147(2014)05-0379-04

作者:

张晓会 ; 张志宏; 徐 勇; 乔鹏飞; 陈 超; 刘冉录

(天津医科大学第二医院泌尿外科,天津市泌尿外科研究所,天津300211)

Author(s):

ZHANG Xiao-hui ; ZHANG Zhi-hong; XU Yong ; QIAO Peng-fei; CHEN Chao ; LIU Ran-lu

(Department of Urology, The Second Hospital ,Tianjin Medical University, Tianjin Institute of Urology ,Tianjin 300211, China)

关键词:

前列腺癌; 合并症; Charlson合并症指数; 早期生存

Keywords:

 ; prostate cancer; complications; Charlson comorbidity index; early survival

分类号:

R737.25

DOI:

-

文献标志码:

A

摘要:

目的：应用Charlson合并症指数(CCI)，探讨合并症对局限性或局部晚期前列腺癌患者早期生存（3年内）的影响，以期提高对合并症治疗的重视。方法：回顾分析198例局限性或局部晚期前列腺癌患者的临床资料，年龄52～83岁，平均年龄71岁。随访生存情况，分析患者的年龄、合并症情况（CCI）、TNM分期、Gleason评分、病理类型、治疗方式及用药信息等因素对患者早期生存的影响，并比较分析患者生存期之间的差异。结果：在前列腺癌确诊后的第3年，3例（1.51％）患者死于前列腺癌进展发生的远处转移，7例（3.53％）患者死于非癌症相关的其他原因（CCI≥2）。单因素分析结果显示，年龄、合并症、用药信息与早期生存相关，CCI≥2的患者中位生存期为26个月。结论：多种因素影响局限性或局部晚期前列腺癌患者的生存与预后，其中合并症是影响患者早期生存的独立因素，积极治疗前列腺癌患者并存的合并症，可能会获得较好的预后。

Abstract:

Objective： To explore the influence of complications on early survival (in 3 years) of patients with localized or locally advanced prostate cancer to enhance public awareness on the therapy of comorbidity. Methods: Clinical data of 198 cases with localized or locally advanced prostate cancer  were retrospectively analyzed，with the patients’ age from 52 to 83 and the average being 71．Following-up survival situation was carried out, to study the impact on early survival and compare survival differences, the author made an analysis of various factors, including: age, reasons for treatment, comorbidity, TNM stage, Gleason score, pathological type, therapy , medication information and so on. Results: In the third year after diagnosis, three patients (1.51%) died from prostate cancer metastasis and seven patients (3.53%) died because of other causes which were not related to prostate cancer. Single factoranalysisresults showed that age, complication, medication information were related to early survival. Furthermore,the median survival time of patients with CCI≥2 was 26 months. Conclusion: Many factors can affect early survival of patients with localized or locally advanced prostate cancer.Complications are independent factors affecting early survival patients. Active treatment of complications in prostate cancer patients may achieve good prognosis results.

参考文献/References:

[1]王延风，杨敏，彭黎黎，等. 合并症对老年非小细胞肺癌患者预后及生存的影响[J]. 中国肿瘤临床与康复, 2012 (3):213
[2]刘倩，王鹏华，张达，等. 糖尿病足感染截肢(趾)相关危险因素分析[J]. 天津医药, 2013,41(2):110
[3]叶定伟. 前列腺癌的流行病学和中国的发病趋势[J]. 中华外科杂志, 2006,44(6):362
[4]D’amico A V, Braccioforte M H, Moran B J, et al. CAUSES OF DEATH IN MEN WITH PREVALENT DIABETES AND NEWLY DIAGNOSED HIGH- VERSUS FAVORABLE-RISK PROSTATE CANCER[J]. Int J Radiat Oncol Biol Phys, 2010,77(5):1329
[5]Ketchandji M, Kuo Y F, Shahinian V B, et al. Cause of death in older men after the diagnosis of prostate Cancer[J]. J Am Geriatr Soc, 2009,57(1):24
[6]Hayes J H, Chen M H, Moran B J, et al. Androgen-suppression therapy for prostate Cancer and the risk of death in men with a history of myocardial infarction or stroke[J]. BJU Int, 2010,106(7):979
[7]Davies B J, Smaldone M C, Sadetsky N A, et al. The impact of obesity on overall and Cancer specific survival in men with prostate Cancer[J]. J Urol, 2009,182(1):112
[8]Alibhai S M, Leach M, Tomlinson G A, et al. Is there an optimal comorbidity index for prostate Cancer?[J]. Cancer, 2008,112(5):1043
[9]Boulos D L, Groome P A, Brundage M D, et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent[J]. Cancer, 2006,106(8):1804
[10]Singh B, Bhaya M, Stern J, et al. Validation of the charlson comorbidity index in patients with head and neck Cancer:a multi-institutional study[J]. Laryngoscope, 1997,107(11 Pt 1):1469
[11]Miller D C, Taub D A, Dunn R L, et al. The impact of co-morbid disease on Cancer control and survival following radical cystectomy[J]. J Urol, 2003,169(1):105
[12]Charlson M E, Pompei P, Ales K L, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation[J]. J Chronic Dis, 1987,40(5):373
[13]Gettman M T, Boelter C W, Cheville J C, et al. Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension[J]. J Urol, 2003,169(4):1282
[14]Kastner C, Armitage J, Kimble A, et al. The charlson comorbidity score: a superior comorbidity assessment tool for the prostate Cancer multidisciplinary meeting[J]. Prostate Cancer Prostatic Dis, 2006,9(3):270
[15]Daskivich T J, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate Cancer and significant comorbidity[J]. Cancer, 2011,117(20):4805; author reply 4805
[16]Schymura M J, Kahn A R, German R R, et al. Factors associated with initial treatment and survival for clinically localized prostate Cancer: results from the CDC-NPCR Patterns of Care Study (PoC1)[J]. BMC Cancer, 2010,10：152
[17]Guzzo T J, Dluzniewski P, Orosco R, et al. Prediction of mortality after radical prostatectomy by Charlson comorbidity index[J]. Urology, 2010,76(3):553
[18]Freeman V L, Durazo-Arvizu R, Arozullah A M, et al. Determinants of mortality following a diagnosis of prostate Cancer in Veterans Affairs and private sector health care systems[J]. Am J Public Health, 2003,93(10):1706
[19]刘兴凯，杨敬进，石歧兴，等. 全雄激素阻断治疗晚期前列腺癌[J]. 辽宁医学杂志, 2005(1):22

相似文献/References:

[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
　YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(05):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
　WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(05):375.
[5]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
　SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(05):401.
[6]管明秀,周云丽,王 萌,等.TuM2-PK，tPSA，fPSA/tPSA和PSAD对PSA灰区前列腺癌诊断价值的比较[J].天津医科大学学报,2016,22(02):140.
　GUAN Ming-xiu,ZHOU Yun-li,WANG-Meng,et al.Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area[J].Journal of Tianjin Medical University,2016,22(05):140.
[7]李 江,张恩龙,赵 阳,等.前列腺癌靶向磁共振成像和光热治疗的实验研究[J].天津医科大学学报,2017,23(02):93.
　LI Jiang,ZHANG En-long,ZHAO Yang,et al.?Experimental research of targeted magnetic resonance imaging and photo thermal therapy for prostate cancer [J].Journal of Tianjin Medical University,2017,23(05):93.
[8]张一然,潘盼,连振鹏,等.磁共振扫描对经直肠超声引导前列腺穿刺活检的影响[J].天津医科大学学报,2017,23(02):99.
　ZHANG Yi-ran,PAN Pan,LIAN Zhen-peng,et al.Effect of magnetic resonance imaging scan on the?transrectal ultrasound?prostate biopsy[J].Journal of Tianjin Medical University,2017,23(05):99.
[9]薄志强,孙桂江,王 丽,等.CtBP2异常表达对前列腺癌PC3细胞增殖效应影响的研究[J].天津医科大学学报,2017,23(02):103.
　BO Zhi-qiang,SUNGui-jiang,WANG Li,et al.Effect of abnormal expression of CtBP2 on the proliferation of prostate cancer cell line PC3[J].Journal of Tianjin Medical University,2017,23(05):103.
[10]徐庆祝,牛远杰.Gleason 10分前列腺癌患者临床特点分析[J].天津医科大学学报,2017,23(04):361.
　XU Qing-zhu,NIU Yuan-jie.Clinical and pathological research of prostate cancer with Gleason score 10[J].Journal of Tianjin Medical University,2017,23(05):361.

备注/Memo

备注/Memo:

作者简介 张晓会（1988-），男，硕士在读，研究方向：泌尿系统肿瘤；通信作者：张志宏，E-mail：Drzhangzhihong@163.com。

常用功能

更新日期/Last Update: 2014-09-25